Description
Product details
Temozolomide 250 mg, marketed under the brand name TMOZOLMIDE 250 by Steris Healthcare, is a potent chemotherapy drug primarily used to treat certain aggressive brain tumors such as glioblastoma multiforme (GBM) and anaplastic astrocytoma. Its mechanism of action involves alkylation of DNA, which damages the cancer cells’ DNA strands, leading to their programmed death and inhibition of tumor growth. This effect is achieved through the addition of a methyl group at the O6 and N7 positions of guanine in DNA. Tumor cells damaged by this process are unable to reproduce and eventually die, making Temozolomide an effective agent in chemotherapy regimens[,]. What are the Benefits of Temozolomide 250 mg? Temozolomide 250 mg offers significant benefits for patients battling brain cancers. It crosses the blood-brain barrier effectively, which allows it to reach tumor cells inside the brain where many other drugs cannot penetrate. This expands its efficacy in treating primary brain tumors and certain metastatic tumors that have spread to the brain. In clinical settings, it has been shown to improve progression-free survival rates and, in some cases, overall survival when used with radiation therapy or alone during maintenance treatment phases[,]. Key Benefits of Temozolomide 250 mg Effective treatment of aggressive brain tumors like glioblastoma multiforme and anaplastic astrocytoma. Can be administered orally, offering convenience compared to intravenous chemotherapy. Ability to cross the blood-brain barrier ensuring targeted therapy within the central nervous system. Well-established as part of the standard Stupp protocol (combined with radiotherapy). May improve quality of life by slowing tumor progression and managing symptoms associated with brain tumors[,]. Side Effects of Temozolomide 250 mg While Temozolomide is effective, it may cause side effects common to chemotherapy medications due to its impact on both cancerous and healthy rapidly dividing cells. Common Side Effects of Temozolomide 250 mg Nausea and vomiting, which can sometimes be severe. Fatigue and weakness. Hair thinning or hair loss. Constipation or diarrhea. Loss of appetite. Mouth sores or changes in taste. Dizziness or headache. Mild skin rashes or itching[,]. Serious Side Effects of Temozolomide 250 mg Significant reduction in blood cell counts causing anemia, leukopenia, or thrombocytopenia (requiring close blood monitoring). Severe infections due to immune suppression. Allergic reactions including swelling, itching, or rash. Liver dysfunction or jaundice. Seizures or neurological symptoms. Unusual bleeding or bruising. Signs of severe allergic reaction like difficulty breathing[,]. Available Substitute for Temozolomide 250 mg There are limited direct substitutes for Temozolomide due to its unique ability to treat brain tumors crossing the blood-brain barrier. Alternatives depend on tumor type and may include other chemotherapy drugs like lomustine (CCNU), carmustine (BCNU), or newer targeted therapies and immunotherapies under clinical trial. However, these alternatives may vary in efficacy and side effect profile and are generally used under oncologist guidance[,]. Dosage Guidelines for Temozolomide 250 mg The dosage of Temozolomide 250 mg (TMOZOLMIDE 250) by Steris Healthcare is carefully tailored based on the type and stage of cancer, body surface area (BSA), and patient tolerance. The standard regimen for newly diagnosed glioblastoma is an oral dose of 75 mg/m² daily during radiotherapy, followed by maintenance cycles of 150 to 200 mg/m² for 5 days every 28 days. Dose adjustments are common based on blood counts and side effects. Strict adherence to the prescribed dosage schedule and monitoring are critical for safety and efficacy.
